Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-NAC: N-acetylcysteine in adults with acute infection or sepsis and liver dysfunction
2026-525895-25-00Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute infection, sepsis and hepatic dysfunction comparing N-acetylcysteine with Placebo (sodium chloride) (2 arms). Primary endpoint: Days alive and out of hospital from randomization to day 14. Planned start Sep 2026; status: authorised.
02
Drugs
acetylcysteine
03
Conditions
acute infectionsepsishepatic dysfunction
Beyond the preview
Go deeper on 2026-525895-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525895-25-00.